A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
Completed · Phase 3 · NCT02927067
Conditions: Cytomegalovirus (CMV)
At a glance
- Research payments reported, 2025
- $6,269
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 553
About the trial
- Sponsor
- Shire (with Takeda Development Center Americas, Inc.)
- Tested
- Maribavir (drug), Valganciclovir (drug), Placebo (other)
- Dates
- Started 2017-04-14; completion 2022-07-01
- Results posted
- Yes
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. A placebo will look like marivabir or valganciclovir but will not have any medicine in it. After treatment, each participant will be followed up for up to 12 weeks. Participants will visit their study clinic up to 18 times during the study.
From ClinicalTrials.gov, last updated 2023-03-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $6,269 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.